GE Spinoff Wins FDA Approval For Prostate Cancer PET Tracer
This article was originally published in The Gray Sheet
Executive Summary
Blue Earth Diagnostics is betting that positron emission tomography imaging to aid recurrent prostate cancer treatment is an untapped market with the FDA approval of its Axumin molecular imaging agent.